Molecular Mechanism of Cynodon dactylon Phytosterols Targeting MAPK3 and PARP1 to Combat Epithelial Ovarian Cancer: A Multifaceted Computational Approach
- PMID: 38961033
- DOI: 10.1007/s12013-024-01375-w
Molecular Mechanism of Cynodon dactylon Phytosterols Targeting MAPK3 and PARP1 to Combat Epithelial Ovarian Cancer: A Multifaceted Computational Approach
Abstract
Epithelial Ovarian Cancer (EOC) presents a global health concern, necessitating the development of innovative therapeutic strategies to combat its impact. This study was employed to investigate the unexplored therapeutic efficacy of Cynodon dactylon phytochemicals against EOC using a multifaceted computational approach. A total of 19 out of 89 rigorously curated phytochemicals were assessed as potential drug targets via ADMET profiling, while protein-protein interaction analysis scrutinized the top 20 hub genes among 264 disease targets, revealing their involvement in cancer-related pathways and underscoring their significance in EOC pathogenesis. In molecular docking, Stigmasterol acetate showed the highest binding affinity (-10.9 kcal/mol) with Poly [ADP-ribose] polymerase-1 (PDB: 1UK1), while Arundoin and Beta-Sitosterol exhibited strong affinities (-10.4 kcal/mol and -10.1 kcal/mol, respectively); additionally, Beta-Sitosterol interacting with Mitogen-activated protein kinase 3 (PDB: 4QTB) showed a binding affinity of -10.1 kcal/mol, forming 2 hydrogen bonds and a total of 10 bonds with 10 residues. Molecular dynamics simulations exhibited the significant structural stability of the Beta-Sitosterol-4QTB complex with superior binding free energy (-36.61 kcal/mol) among the three complexes. This study identified C. dactylon phytosterols, particularly Beta-Sitosterol, as effective in targeting MAPK3 and PARP1 to combat EOC, laying the groundwork for further experimental validation and drug development efforts.
Keywords: Cynodon dactylon; ADMET; Epithelial Ovarian Cancer; MD Simulation; Molecular Docking; Network Pharmacology.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
The drug discovery candidate for targeting PARP1 with Onosma. Dichroantha compounds in triple-negative breast cancer: A virtual screening and molecular dynamic simulation.Comput Biol Chem. 2025 Oct;118:108471. doi: 10.1016/j.compbiolchem.2025.108471. Epub 2025 Apr 15. Comput Biol Chem. 2025. PMID: 40252254
-
Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.Pathol Res Pract. 2020 Feb;216(2):152794. doi: 10.1016/j.prp.2019.152794. Epub 2019 Dec 20. Pathol Res Pract. 2020. PMID: 31902551
-
Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.J Exp Clin Cancer Res. 2019 Aug 7;38(1):345. doi: 10.1186/s13046-019-1329-2. J Exp Clin Cancer Res. 2019. PMID: 31391118 Free PMC article.
-
Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.Curr Pharm Biotechnol. 2018;19(14):1114-1121. doi: 10.2174/1389201020666181226123054. Curr Pharm Biotechnol. 2018. PMID: 30585545 Review.
-
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.Int J Environ Res Public Health. 2022 Jul 14;19(14):8577. doi: 10.3390/ijerph19148577. Int J Environ Res Public Health. 2022. PMID: 35886427 Free PMC article. Review.
References
-
- Huang, X., Li, X.-Y., Shan, W.-L., Chen, Y., Zhu, Q., & Xia, B.-R. (2023). Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1131342 .
-
- Sung, S., Hong, Y., Kim, B., Choi, J., Kim, J. W., Park, S. & & Park, S. K. (2023). Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko‐EVE. Cancer Medicine, 12(7), 8742–8753. https://doi.org/10.1002/cam4.5612 .
-
- Ding, M., Dong, C., Mao, Y., Liu, S., Zhao, Y., & Wang, X. (2023). A combined network pharmacology and molecular biology approach to investigate the potential mechanisms of G-M6 on ovarian cancer. Bioorganic Chemistry, 138, 106657 https://doi.org/10.1016/j.bioorg.2023.106657 . - DOI - PubMed
-
- Kalimuthu, A. K., Pavadai, P., Panneerselvam, T., Babkiewicz, E., Pijanowska, J., Mrówka, P., & Kunjiappan, S. (2022). Cytotoxic potential of bioactive compounds from Aspergillus flavus, an endophytic fungus isolated from Cynodon dactylon, against breast cancer: experimental and computational approach. Molecules, 27(24), 8814 https://doi.org/10.3390/molecules27248814 . - DOI - PubMed - PMC
-
- Gao, X., & Homayoonfal, M. (2023). Exploring the anti-cancer potential of Ganoderma lucidum polysaccharides (GLPs) and their versatile role in enhancing drug delivery systems: a multifaceted approach to combat cancer. Cancer Cell International, 23(1), 324 https://doi.org/10.1186/s12935-023-03146-8 . - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous